- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic cancer: Update on immunotherapies and algenpantucel-L
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 12, Issue 3, Pages 563-575
Publisher
Informa UK Limited
Online
2015-12-01
DOI
10.1080/21645515.2015.1093264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic cancer, treatment options, and GI-4000
- (2016) Marion L Hartley et al. Human Vaccines & Immunotherapeutics
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
- (2015) Angus George Dalgleish et al. JOURNAL OF CLINICAL ONCOLOGY
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity
- (2015) Marco de Bruyn et al. Frontiers in Oncology
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma
- (2014) Takeshi Terashima et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Pancreatic Cancer-Induced Cachexia Is Jak2-Dependent in Mice
- (2014) Marine Gilabert et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
- (2014) Y. Zhang et al. Cancer Immunology Research
- The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
- (2014) D. T. Fearon Cancer Immunology Research
- Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
- (2013) C. Bosetti et al. ANNALS OF ONCOLOGY
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients
- (2013) Ryuji Okuyama et al. OncoImmunology
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
- (2012) Hidekazu Kameshima et al. CANCER SCIENCE
- Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
- (2012) Jeffrey M. Hardacre et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Immunotherapy updates in pancreatic cancer: are we there yet?
- (2012) Krishna Soujanya Gunturu et al. Therapeutic Advances in Medical Oncology
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
- (2011) William F. Regine et al. ANNALS OF SURGICAL ONCOLOGY
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
- (2011) Yefei Rong et al. CLINICAL AND EXPERIMENTAL MEDICINE
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Potential targets for pancreatic cancer immunotherapeutics
- (2011) Lindzy F Dodson et al. Immunotherapy
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner
- (2010) Neta Erez et al. CANCER CELL
- Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
- (2010) Synne Wedén et al. INTERNATIONAL JOURNAL OF CANCER
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
- (2009) Motoki Miyazawa et al. CANCER SCIENCE
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
- (2008) R. F. Hwang et al. CANCER RESEARCH
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
- (2008) Lei Geng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
- (2008) Agnes Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance
- (2007) Bruce A. Macher et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started